Description

FLModafinil (CRL 40,940) Tablets

Introduction

FLModafinil (CRL-40,940) Tablets represent a dedicated research product, strictly intended for scientific exploration and devoid of any connection to human consumption. Capitalizing on the distinctive compound FLModafinil, these tablets provide researchers with a tool to investigate its potential benefits in the realms of wakefulness, fatigue reduction, and motivation enhancement.

Key Characteristics

FLModafinil, also known as CRL-40,940, exhibits a unique pharmacological profile as a derivative of modafinil. It stands out for its ability to promote wakefulness and cognitive enhancements without the stimulant properties typically associated with traditional wakefulness-promoting agents.

Research Applications

FLModafinil Tablets find diverse applications in research domains, serving as a valuable tool for investigating its potential to enhance wakefulness, reduce fatigue, and improve motivation—all crucial aspects contributing to a comprehensive understanding of cognitive function.

Research Benefits

Potential to Enhance Wakefulness

Studies indicate that FLModafinil holds promise in enhancing wakefulness without the typical side effects associated with traditional stimulants, making it a subject of interest for research into sleep-related disorders.

May Reduce Fatigue

Research suggests that FLModafinil may have fatigue-reducing effects, potentially contributing to improved cognitive performance and overall well-being in situations of extended wakefulness.

May Improve Motivation

Preliminary studies propose that FLModafinil may have motivational-enhancing effects, making it a potential candidate for research into motivation-related disorders.

Summary

FLModafinil (CRL-40,940) Tablets, designed exclusively for research purposes, offer a unique avenue for investigating the potential benefits of FLModafinil in enhancing wakefulness, reducing fatigue, and improving motivation. Researchers can explore its distinctive pharmacological characteristics to contribute to the understanding of cognitive enhancers.

References

1. Luca G, Bandarabadi M, Konofal E, Lecendreux M, Ferrié L, Figadère B, Tafti M. Lauflumide (NLS-4) Is a New Potent Wake-Promoting Compound. Front Neurosci. 2018 Aug 15;12:519. doi: 10.3389/fnins.2018.00519. PMID: 30158846; PMCID: PMC6104159. [Read More]
2. Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, Han X, Dong Y. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013 Dec 3;8(12):e81802. doi: 10.1371/journal.pone.0081802. PMID: 24312590; PMCID: PMC3849275. [Read More]
3. Asociación RUVID. “Dopamine regulates the motivation to act, study shows.” ScienceDaily. ScienceDaily, 10 January 2013. <www.sciencedaily.com/releases/2013/01/130110094415.htm>. [Read More]